15:I[66739,["/_next/static/chunks/0_jglizaxuvid.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/00yc4h63rurg4.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/01b21njbdx~~m.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/14s118kzsmuz9.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/166.u_60qj09..js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0g9_wl34k-6l4.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0~r4f.cjjsl~b.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx"],"default"] 17:I[38632,["/_next/static/chunks/0qqtp3r0h7kah.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx","/_next/static/chunks/0iukvycbd42rl.js?dpl=dpl_3DD9m2VJCfF4backj8XFu57cygkx"],"IconMark"] 16:T4f2,

Kyle Bergacker joins Sam Vadas to discuss Novo Nordisk (NVO) earnings. Shares of the biotech pharmaceutical company are down following its 2Q report. Kyle discusses the lowered sales growth in its guidance as well as combatting "copy cat" medications from telehealth companies. He adds commentary on the company's GLP-1 weight loss drugs and what it means in regards to the long-term outlook for Novo Nordisk.

======== Schwab Network ========

Empowering every investor and trader, every market day.

Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe

Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185

Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7

Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch

Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore

Watch on DistroTV - https://www.distro.tv/live/schwab-network/

About Schwab Network - https://schwabnetwork.com/about

NVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats

Schwab Network

NVO Earnings In Focus: Weight Loss Drugs, Combatting Copy Cats